Q32 Bio announced that it will announce the latest breakthrough results from part B of the Signal-AA clinical trial of Bempikibart to treat alopecia areata at the 2026 European Society of Dermatology and Venereology conference.

Zhitongcaijing · 1d ago
Q32 Bio announced that it will announce the latest breakthrough results from part B of the Signal-AA clinical trial of Bempikibart to treat alopecia areata at the 2026 European Society of Dermatology and Venereology conference.